Morphic Holding, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MORF research report →
Companywww.morphictx.com
Morphic Holding, Inc. , a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; and preclinical trial to treat idiopathic pulmonary fibrosis and fibrosis diseases.
- CEO
- Praveen P. Tipirneni
- IPO
- 2019
- Employees
- 128
- HQ
- Waltham, MA, US
Price Chart
Valuation
- Market Cap
- $2.86B
- P/E
- -15.88
- P/S
- 5493.87
- P/B
- 3.47
- EV/EBITDA
- -15.80
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -109.40%
- Op Margin
- -34296.74%
- Net Margin
- -29192.90%
- ROE
- -29.08%
- ROIC
- -25.55%
Growth & Income
- Revenue
- $521.00K · -99.26%
- Net Income
- $-152,095,000 · -157.61%
- EPS
- $-3.59 · -131.61%
- Op Income
- $-178,686,000
- FCF YoY
- -12.05%
Performance & Tape
- 52W High
- $57.00
- 52W Low
- $19.34
- 50D MA
- $44.96
- 200D MA
- $33.56
- Beta
- 1.49
- Avg Volume
- 2.45M
Get TickerSpark's AI analysis on MORF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 16, 24 | Edwards Martin | sell | 2,376 |
| Aug 16, 24 | Edwards Martin | sell | 17,550 |
| Aug 16, 24 | Edwards Martin | sell | 12,535 |
| Aug 16, 24 | Edwards Martin | sell | 23,168 |
| Aug 16, 24 | Edwards Martin | sell | 9,996 |
| Aug 16, 24 | Edwards Martin | sell | 24,000 |
| Aug 16, 24 | SLATTERY JOSEPH P | sell | 12,000 |
| Aug 16, 24 | SLATTERY JOSEPH P | sell | 12,535 |
| Aug 16, 24 | SLATTERY JOSEPH P | sell | 24,000 |
| Aug 16, 24 | SLATTERY JOSEPH P | sell | 9,615 |
Our MORF Coverage
We haven't published any research on MORF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate MORF Report →